FDA does a triple-take on Tamiflu

Speaking of pediatric safety, the FDA also plans to review Roche's Tamiflu and GlaxoSmithKline's Relenza at its advisory committee confab Nov. 27-28. At issue: the anti-influenza drugs' potential neurological side effects in kids.

The FDA started looking at the neurological effects of these drugs in 2005, when it began receiving reports of hallucinations and convulsions. Twenty-five kids have died while on Tamiflu, most of them in Japan, where regulators restricted usage of the drug in teens, sending sales of the drug in all age groups tumbling. There have been no reports of Relenza-related deaths, but regulators say the drug causes similar neurological side effects.

The agency is recommending a change to the drugs' labeling to alert doctors about these possible side effects. But Roche says there's no evidence to link the deaths with Tamiflu, and that flu patients have exhibited similar symptoms without the help of the drug. More than 1,700 of the 1,808 adverse-event reports originated in Japan, a company spokesman said, and 81 percent of those were "non-serious." It's worth noting, though, that Japan has been the biggest market for the drug, where 75 percent of the prescriptions for it are written.

- see the FDA's briefing on Tamiflu
- read the report from the Washington Post
- read Roche's response

Related Articles:
Tamiflu's Japanese sales to drop by half. Report
Roche's Tamiflu ads spark criticism. Report
EU approves Tamiflu for children. Report

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.